Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $56.91 Consensus Price Target from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned an average rating of “Moderate Buy” from the fourteen research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $56.9091.

A number of equities analysts have recently weighed in on JANX shares. HC Wainwright lowered their target price on Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, December 2nd. Wedbush restated an “outperform” rating and issued a $45.00 price target (down from $76.00) on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Piper Sandler decreased their price objective on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating on the stock in a report on Friday, January 16th. Barclays lowered their price objective on Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Finally, Guggenheim dropped their target price on Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating for the company in a report on Friday, February 27th.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $13.18 on Monday. Janux Therapeutics has a 52 week low of $12.12 and a 52 week high of $35.34. The company has a market capitalization of $801.74 million, a price-to-earnings ratio of -7.20 and a beta of 2.88. The company has a 50-day simple moving average of $13.68 and a 200 day simple moving average of $19.32.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.14. The company had revenue of $7.88 million during the quarter, compared to the consensus estimate of $0.08 million. Sell-side analysts forecast that Janux Therapeutics will post -1.38 EPS for the current year.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, insider Thomas Diraimondo sold 2,505 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $34,393.65. Following the completion of the sale, the insider owned 124,425 shares of the company’s stock, valued at $1,708,355.25. The trade was a 1.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO David Alan Campbell sold 8,072 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $110,828.56. Following the transaction, the chief executive officer owned 284,982 shares in the company, valued at approximately $3,912,802.86. The trade was a 2.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 19,033 shares of company stock valued at $261,323 in the last quarter. Company insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in JANX. Janus Henderson Group PLC grew its position in Janux Therapeutics by 13.8% during the fourth quarter. Janus Henderson Group PLC now owns 5,350,453 shares of the company’s stock worth $73,850,000 after buying an additional 649,341 shares in the last quarter. State Street Corp increased its stake in Janux Therapeutics by 103.8% during the 4th quarter. State Street Corp now owns 3,853,951 shares of the company’s stock worth $53,185,000 after acquiring an additional 1,962,486 shares during the period. Vanguard Group Inc. raised its holdings in Janux Therapeutics by 10.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock valued at $59,074,000 after acquiring an additional 227,676 shares in the last quarter. Prosight Management LP lifted its position in shares of Janux Therapeutics by 176.5% during the 4th quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock valued at $33,017,000 after acquiring an additional 1,527,173 shares during the period. Finally, Orbimed Advisors LLC lifted its position in shares of Janux Therapeutics by 10.7% during the 4th quarter. Orbimed Advisors LLC now owns 1,954,426 shares of the company’s stock valued at $26,971,000 after acquiring an additional 188,326 shares during the period. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.